StockData
Alzamend Neuro, Inc. logo

Alzamend Neuro, Inc. (ALZN) stock

ALZNNasdaqPharmaceutical PreparationsFiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 10, 2026Score 4/30
$1.04−0.09 (-7.96%)

Close on Nov 18, 2026Market cap $5.02MP/E –Yield –

Alzamend Neuro operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Alzamend Neuro's operating cash flow for the twelve months ending Jul 31, 2026 was -$6.84M. For fiscal 2026 it was -$8.07M. The highest annual figure on record is -$2.35M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2026Apr 30, 2026-$8.07M–
FY2025Apr 30, 2025-$6.57M–
FY2024Apr 30, 2024-$8.27M–
FY2023Apr 30, 2023-$8.92M–
FY2022Apr 30, 2022-$6.61M–
FY2021Apr 30, 2021-$2.71M–
FY2020Apr 30, 2020-$2.35M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jul 31, 2026-$1.14M–
Q4 FY2026CQ1 2026Apr 30, 2026-$2.80M–
Q3 FY2026CQ4 2025Jan 31, 2026-$1.74M–
Q2 FY2026CQ3 2025Oct 31, 2025-$1.17M–
Q1 FY2026CQ2 2025Jul 31, 2025-$2.36M–
Q1 FY2025CQ2 2024Jul 31, 2024-$1.06M–
Q4 FY2024CQ1 2024Apr 30, 2024-$1.43M–
Q3 FY2024CQ4 2023Jan 31, 2024-$2.03M–
Q2 FY2024CQ3 2023Oct 31, 2023-$1.51M–
Q1 FY2024CQ2 2023Jul 31, 2023-$3.30M–
Q4 FY2023CQ1 2023Apr 30, 2023-$2.24M–
Q3 FY2023CQ4 2022Jan 31, 2023-$1.81M–
Q2 FY2023CQ3 2022Oct 31, 2022-$2.34M–
Q1 FY2023CQ2 2022Jul 31, 2022-$2.54M–
Q4 FY2022CQ1 2022Apr 30, 2022-$1.56M–
Q3 FY2022CQ4 2021Jan 31, 2022-$1.78M–
Q2 FY2022CQ3 2021Oct 31, 2021-$2.05M–
Q1 FY2022CQ2 2021Jul 31, 2021-$1.22M–
Q4 FY2021CQ1 2021Apr 30, 2021-$1.26M–
Q3 FY2021CQ4 2020Jan 31, 2021-$806.13K–
Q2 FY2021CQ3 2020Oct 31, 2020-$442.93K–
Q1 FY2021CQ2 2020Jul 31, 2020-$205.10K–

More Alzamend Neuro figures

See a number that looks wrong?